Seeking Alpha Market Currents
Article : Gilead Sciences: A Unique Stallion
Some analysts believe now that the $11 billion Gilead paid for the drug is now estimated to bring in more than $100 billion in sales revenues over a decade.
Yahoo Finance Business Wire
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma
-- 57 Percent Overall Response Rate and Median Duration of Response of 12.5 Months in Heavily Pre-Treated Patients --
-- Data Presented at American Society of Hematology Annual Meeting --
Business Wire Gilead Sciences, Inc. 7 hours ago
not FB idiot on twitter, here's the link
Adam Feuerstein @adamfeuerstein 10m
My 2 cents: $GERN higher Mon/Tues on confirmed/solid bone marrow response + some evidence clinical benefit. No idea how much.
it is never a done deal unti FDA approves it and with FDA approval will come big gains
someone pushed wrong button